Information Provided By: 
Fly News Breaks for November 5, 2019
TNDM
Nov 5, 2019 | 07:56 EDT
Cowen analyst Ryan Blicker noted the after-market weakness in Tandem Diabetes shares and said it appears to be overdone. The analyst said Q3 results were solid and management's guidance while not pristine, made sense and the weakness should be transitory. Blicker reiterated his Outperform rating and $75 price target on Tandem Diabetes shares.
News For TNDM From the Last 2 Days
There are no results for your query TNDM
